(Q33782344)

29 July 2017

1 reference

title

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis (English)

1 reference

29 July 2017

0 references

1 reference

1 reference

Maini RN

1

1 reference

29 July 2017

Taylor PC

2

1 reference

29 July 2017

Paleolog E

3

1 reference

29 July 2017

Charles P

4

1 reference

29 July 2017

Ballara S

5

1 reference

29 July 2017

Brennan FM

6

1 reference

29 July 2017

Feldmann M

7

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

Annals of the Rheumatic Diseases

29 July 2017

published in

1 reference

29 July 2017

volume

58 Suppl 1

1 reference

29 July 2017

page(s)

I56-60

1 reference

The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766574

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766574

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766574

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766574

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766574

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

4 July 2018

1 reference

12 December 2020

In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects

1 reference

12 December 2020

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis

1 reference

12 December 2020

Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy

1 reference

12 December 2020

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis

1 reference

12 December 2020

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.58.2008.I56

1 reference

29 July 2017

1 reference

29 July 2017

1 reference